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Attentional bias in substance-dependent individuals is the tendency to automatically direct the attention to substance-related cues in the
environment. Attentional bias is known to be associated with clinical measures such as relapse or successful quitting in smokers. It has
been suggested that attentional bias emerges as a consequence of dopaminergic activity evoked by substance-related cues. The current
functional magnetic resonance imaging study employed a dopaminergic challenge in order to test whether brain activation associated
with attentional bias in smokers could be modulated by a dopamine antagonist. A total of 25 smokers were compared with 24 controls.
Participants were scanned twice while performing a pictorial attentional bias task. Haloperidol (2mg), a selective D2/D3 dopamine
antagonist, or placebo was orally administered 4 h before each scanning session in a double-blind randomized cross-over design. Imaging
analyses were performed in a priori selected regions of interest. Results showed that smokers had enhanced brain activation compared
with controls in the dorsal anterior cingulate cortex (dACC), right dorsolateral prefrontal cortex (r-DLPFC), and left superior parietal
lobe (I-SPL) after placebo. Groupmedication interactions were found in the dACC and r-DLPFC, with no differences between groups
in these regions after haloperidol. The current findings suggest that a pharmacologically induced reduction in dopamine normalizes brain
activation associated with attentional bias in the dACC and DLPFC in smokers, probably because salience of these cues is no longer
detected when dopamine activity is reduced.
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Substance abuse and addiction are associated with en-
hanced processing of substance-related cues (eg, Franken
et al, 2003; Kuhn and Gallinat, 2011). Attentional bias is one
of the mechanisms underlying enhanced processing of these
cues and is defined as the tendency of substance-dependent
people to automatically and involuntarily allocate and
maintain their attention to conditioned drug cues (for
reviews, see Field and Cox, 2008; Franken, 2003; Robbins
and Ehrman, 2004). Attentional bias has been linked to
craving (Field et al, 2009b) as well as to the temptation to
use substances (Waters et al, 2012), treatment outcome
(Carpenter et al, 2006; Cox et al, 2002), and relapse rates
(Marissen et al, 2006; Waters et al, 2003). Preliminary
evidence has further suggested that attentional bias extinc-
tion training reduces conditioned cigarette craving in
smoking males (Attwood et al, 2008) and drinking behavior
in alcohol-dependent patients (Fadardi and Cox, 2009;
Schoenmakers et al, 2010). However, it seems that a single
training session is not successful to reduce smoking
behavior (Attwood et al, 2008; Field et al, 2009a; McHugh
et al, 2010).
Theoretical models propose that attentional bias is a
consequence of a dopamine signal that triggers attention to
substance-related cues (Franken, 2003; Robinson and
Berridge, 2003). After repeated drug intake, substance-
related cues become conditioned cues and elicit dopami-
nergic activity (Volkow et al, 2006; Wong et al, 2006; Zijlstra
et al, 2008) thereby signaling the expectation of a future
reward (ie, the intake of the substance of abuse). Gradually,
the dopaminergic system becomes sensitized for substance-
related cues so that they become extremely salient, become
the focus of attention and elicit behaviors like drug seekingReceived 16 May 2012; revised 25 June 2012; accepted 3 July 2012
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and consumption (Phillips et al, 2003; Robinson and
Berridge, 2008). Consequently, it can be predicted that
attentional bias will be attenuated when dopamine is no
longer able to signal the salience of conditioned substance-
related cues. A few studies tested this hypothesis. Two
studies used acute tyrosine/phenylalanine depletion to
reduce dopamine levels in smokers (Hitsman et al, 2008;
Munafo et al, 2007). Both studies found that attentional bias
in smokers was reduced when dopamine levels were
decreased. Similar results were found in heroin users, in
which attentional bias was attenuated after a single dose of
the dopamine antagonist haloperidol (Franken et al, 2004).
As these studies did not measure brain activation, it is not
yet known whether a pharmacologically induced reduction
in dopamine also reduces brain activation in those regions
involved in salience detection and attentional bias. Only
recently progress has been made to elucidate the neurobio-
logical substrate of attentional bias. Functional magnetic
resonance imaging (fMRI) has shown that attentional bias is
associated with increased activation in brain regions
innervated by dopaminergic projection such as the ACC
and the ventral striatum (Janes et al, 2010a; Luijten et al,
2011; Nestor et al, 2011; Vollstadt-Klein et al, 2012). In
addition, dorsolateral and inferior frontal regions, as well as
the insula, amygdala, superior parietal, and superior and
middle temporal gyri were implicated in attentional bias for
substance-related cues (Ersche et al, 2010; Hester and
Garavan, 2009; Janes et al, 2010a; Luijten et al, 2011;
Vollstadt-Klein et al, 2012). Ersche et al (2010) showed that a
dopamine agonist enhanced attentional bias and associated
brain activation in the left ventral prefrontal cortex and the
cerebellum in high-compulsive stimulant dependent indivi-
duals, whereas it reduced activation in these regions in low-
compulsive stimulant users. The Ersche et al study could not
demonstrate a reduction in attentional bias and associated
brain activation following administration of the dopamine
antagonist amisulpride. Consequently, it is still unknown
whether a pharmacologically induced reduction in dopa-
mine levels could normalize brain activation associated with
attentional bias. In this study, attentional bias-related brain
activation was measured twice in smokers and non-smokers
using an attentional bias task involving pictorial stimuli
(Luijten et al, 2011). The D2/D3 dopamine antagonist
haloperidol was used to reduce dopamine levels and was
compared with placebo in a double-blind randomized cross-
over design. Based on theoretical accounts and our previous
study in smokers (Luijten et al, 2011), we hypothesized that
brain activation associated with attentional bias in dopami-
nergic innervated regions such as the ACC and other
prefrontal regions will normalize in smokers after haloper-
idol administration. That is, no differences between smokers
and non-smokers in attentional bias-related brain activation
were expected after haloperidol.
MATERIALS AND METHODS
Participants
A total of 25 smokers and 25 non-smokers participated in
this study. Data from one non-smoker were discarded
because of technical problems during data analyses. The
final sample consisted of 25 smokers (mean age¼ 22.56
years, SD¼ 2.84, 18 males) and 24 non-smokers (mean
age¼ 21.75 years, SD¼ 1.78, 14 males). Smokers smoked at
least 15 cigarettes per day (mean¼ 19.12, SD¼ 3.37; range
15–25) for a duration of at least three years (mean¼ 7.20,
SD¼ 3.01, range 3–14). The average score on the Fager-
stro¨m Test for nicotine dependence (Vink et al, 2005) for
smokers was 3.80, SD¼ 3.37, range 1–8. Non-smokers had
smoked ten cigarettes or less during their lifetime
(mean¼ 1.73, SD¼ 2.62, range 0–10). Participants under-
went a medical examination by a psychiatrist to assure
eligibility for a single dose of 2mg oral haloperidol (for
details, see Supplementary materials). Exclusion criteria for
both groups were (a) current substance abuse or depen-
dence (other than nicotine for smokers), (b) any physical or
psychological illness, (c) any use of psychotropic medica-
tion or medication that may affect blood circulation and/
or respiration, (d) fMRI contraindications, and (e) left
handedness. There were no significant differences between
the groups in age, t(47)¼ 2.40; NS, or gender, w (1,
n¼ 49)¼ 0.32; NS. The study was conducted in accordance
with the Declaration of Helsinki and all procedures were
carried out after participants signed informed consent. The
ethics committee of Erasmus MCFUniversity Medical
Centre Rotterdam approved this study.
Dopaminergic Manipulation
Participants were administered a single oral dose of 2mg
haloperidol and a placebo employing a double-blind
randomized cross-over design. Haloperidol is a selective
post-synaptic dopamine D2/D3 receptor antagonist. Using
positron emission tomography (PET), it has been shown
that striatal D2 receptor occupancy 3 h after administration
of 2mg haloperidol is 18% and 52% after 6 h (Nordstrom
et al, 1992). The present fMRI session took place 4 h after
administration which, according to the Nordstrom study,
results in about 30% D2 receptor occupancy. The dose and
time interval was further based on previous studies using
haloperidol (Franken et al, 2004, 2008; Mahler and de Wit,
2005) that showed attenuated cue-reactivity in smokers
(Mahler and de Wit, 2005) and attentional bias in heroin
users (Franken et al, 2004) after haloperidol. No side effects
were reported by the participants. Participants’ guesses on
the type of medication they received for each scanning
session were not above chance (48.97% of the participants
correctly indicated in which test occasion they received
haloperidol, p¼ 0.56).
Procedures
Two scanning sessions were scheduled that were separated
by 1 week. Smokers were not allowed to smoke after taking
the medication until scanning was finished to ensure that
indirect nicotine effects on dopamine levels did not
interfere with the binding of haloperidol to D2/D3 receptors
in the brain. Breath carbon monoxide (CO) concentration
was measured in all subjects using a calibrated Micro +
Smokerlyzer (Bedfont Scientific, Rochester, UK). Smokers
completed the FTND (Heatherton et al, 1991; Vink et al,
2005) to measure nicotine dependence on the first scanning
session only and the Questionnaire of Smoking Urges (QSU;
Cox et al, 2002) to indicate their current subjective craving
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for a cigarette during both scanning sessions. Participants
performed the attentional bias line-counting (ABLC) task
during fMRI scanning. Smokers indicated their craving
levels on a 100-point visual analog scale (VAS) immediately
before and after task performance.
Task Paradigm
The ABLC task was used to measure brain activation related
to attentional bias, and has previously been described by
Luijten et al (2011). In each trial, a picture with either
smoking-related stimuli (people engaged in smoking
behavior or smoking-related objects) or neutral stimuli
(people engaged in non-smoking behavior or neutral
objects) was presented for 900ms (Figure 1). Two to five
lines were displayed within each picture, with semi-
randomly distributed spaces between these lines. Instruc-
tions for participants varied over blocks. In one block
(counting lines), participants were asked to count the
number of lines presented in the picture and to press the
corresponding button as fast as possible. In the other block
(naming pictures), participants had to indicate whether the
content of the picture included smoking-related stimuli or
neutral stimuli by pressing the corresponding button.
Within each block, smoking-related and neutral pictures
were semi-randomly presented. Seventy-two trials were
presented for each condition: line-counting smoke picture
(LCSP), line-counting neutral picture (LCNP), picture-
naming smoke picture (PNSP), and picture-naming neutral
picture (PNNP). Based on these conditions, four contrasts
can be defined for analyses. The main contrast reflecting
brain activation associated with attentional bias is the LCSP
minus LCNP contrast. For the line-counting condition,
smoking cues are unrelated to task performance so that
brain activation for LCSP relative to LCNP shows the
disruption of ongoing behavior (line counting) because of
the enhanced attentional and motivational properties of the
smoking pictures. The other three contrasts do not reflect
attentional bias and accordingly are not associated with the
main focus of this paper. See Supplementary materials for
the definition and results of these contrasts.
Data Analyses Questionnaires and Behavioral
Performance
A group (smokers vs non-smokers)  medication (placebo
vs haloperidol) repeated-measures analyses of variance
(RM-ANOVA) was applied to analyze CO levels. A group
medication picture (smoking-related pictures vs neutral
pictures) RM-ANOVA was performed to investigate reac-
tion times and accuracy during line counting. QSU craving
scores in smokers were analyzed with medication as a single
within-subject factor. To investigate the effect of task
performance on craving levels, a medication  time
(before vs after task performance) RM-ANOVA was
performed for craving VAS scores.
Image Acquisition
Imaging data were acquired on a 3T GE Healthcare (The
Discovery MRI 750 3.0T, Milwaukee, WI) scanner. Blood
oxygen level-dependent sensitive functional T2*-weighted
images were acquired in 44 axial slices covering the entire
supratentorial brain with a repetition time (TR) of 2500ms,
echo time (TE) of 30ms, field of view (FOV) of 240mm, and
isotropic voxel size of 2.5mm3. A structural three-dimen-
sional (3D) inversion recovery fast spoiled gradient echo
T1-weighted image was acquired in 164 contiguous axial
slices with TR of 7.9ms, TE of 3.1ms, FOV of 240mm, and
isotropic voxel size of 1mm3 for anatomical reference.
Image Processing
Imaging data were analyzed using SPM8 (Statistical
Parametric Mapping; Wellcome Trust Centre for Neuroima-
ging, London, UK). Preprocessing of the functional data
included realignment and unwarping of functional images.
The anatomical scan was co-registered to the mean T2*-
weighted image and subsequently segmented into grey and
white matter. Segmentation parameters were used for
normalization using the SPM T1 MNI template. Functional
scans were spatially smoothed using a full-width at half-
maximum Gaussian kernel of 8mm. Correct trials for the
four conditions (LCSP, LCNP, PNSP, and PNNP) were
modeled in the context of the general linear model for both
medication conditions, using delta functions convolved
with a canonical hemodynamic response function. Incorrect
trials were modeled separately as regressors of non-interest.
The contrast reflecting brain activation associated with
attentional bias (LCSP minus LCNP) was calculated for each
individual for both medication conditions. Subsequently, a
random effects RM-ANOVA with group as between-subject
factor and medication as within-subject factor was
performed to investigate groupmedication interactions.
Between group and between medication t-tests were
performed (ie, differences between groups for placebo and
haloperidol separately and medication effects in smokers
and non-smokers separately), masked inclusively by voxels
Figure 1 The attentional bias line-counting task.
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showing a groupmedication interaction in the RM-
ANOVA (po0.01 uncorrected), thus ensuring that group
differences and medication effects met the requirement of a
groupmedication interaction. Furthermore, we report
results for the between group two sample t-test for placebo
without masking for the interaction effect, with the aim to
replicate findings from our previous study (Luijten et al,
2011). Finally, cue-induced craving during task perfor-
mance was calculated for each smoker for placebo and
haloperidol separately (craving VAS score after task
performance minus craving VAS score before task perfor-
mance) and was correlated with brain activation associated
with attentional bias in each medication condition sepa-
rately. Given findings of previous studies the ACC, superior
parietal lobe (SPL), superior temporal gyrus, dorsolateral
prefrontal gyrus (DLPFC), inferior frontal gyrus, amygdala,
insula, and nucleus accumbens (NACC) were selected as a
priori regions of interest. ROIs were defined using the
automatic anatomical labeling (AAL) atlas (Tzourio-Ma-
zoyer et al, 2002). As the NACC is not included in the AAL
atlas, a 10mm sphere with MNI coordinates±10 12 -2 was
created as a ROI for the NACC (Knutson et al, 2008).
Results were thresholded at po0.05, family wise error
(FWE) corrected for multiple comparisons across the search
volume (small volume correction: Friston et al, 1996;
Worsley et al, 1996). In order to do so, analyses were first
thresholded at po0.001 uncorrected with 20 contingently
activated voxels (160mm3), and then corrected using a
small volume correction (po0.05 FWE corrected) in which
the search volume was defined by the AAL template
corresponding to the a priori defined ROI.
RESULTS
Breath CO Levels and Questionnaire Data
Smokers had a higher breath CO concentration
(Mhaloperidol¼ 6.20, SD¼ 3.39, Mplacebo¼ 6.72, SD¼ 3.50) than
non-smokers (Mhaloperidol¼ 1.42, SD¼ 0.78, Mplacebo¼ 1.67,
SD¼ 0.64), F(1, 47)¼ 55.15, po0.001. CO levels did not
differ between medication conditions, F(1, 47)¼ 1,91, NS.
Haloperidol did not influence QSU (Mhaloperidol¼ 38.03,
SD¼ 11.80, Mplacebo¼ 39.71, SD¼ 11.48) and VAS craving
scores. However, VAS craving scores increased after task
performance confirming the presence of cue-evoked craving,
F(1, 24)¼ 21.36, po0.001, (Mhaloperidol/before¼ 58.96, SD¼ 21.49,
Mhaloperidol/after¼ 67.00, SD¼ 17.84, Mplacebo/before¼ 62.60,
SD¼ 23.21, Mplacebo/after¼ 68.64, SD¼ 23.38).
Behavioral Performance
Accuracy scores and reaction times are displayed in
Figure 2. Repeated-measures analysis for performance
accuracy did not show a main effect of group
F(1, 47)¼ 2.96, NS. A main effect of medication showed
that haloperidol decreased task performance relative to
placebo, F(1, 47)¼ 10.36, po0.01. Furthermore, a main
effect of picture was found for accuracy (F(1, 47)¼ 11.10,
po0.01), with both groups performing less accurately for
line counting in smoking-related pictures than in neutral
pictures. Regarding reaction times, no main effect of group
or medication was found, both F value’so3.71, NS. A main
effect of picture was found, F(1, 37)¼ 4.14, po0.05,
indicating that reaction times to smoking-related pictures
were faster. No interaction effects were found, all F
value’so2.87, NS. The combination of reduced accuracy
and faster reaction times to smoking-related pictures
suggests that there may be an impulsive response style to
smoking-related pictures in both groups.
Imaging Results
After placebo, smokers showed attentional bias-related
brain activation (ie, more activation than controls on the
LCSP minus LCNP contrast) in the dorsal zone of the ACC
(dACC), the left SPL and the right DLPFC (r-DLPFC). After
masking for the groupmedication interaction, group
differences remained present in the dACC and the r-DLPFC.
No differences between groups were found in attentional
bias-related brain activation after haloperidol administra-
tion. See Figure 3 and Table 1 for details. These findings
suggest that the dACC, r-DLPFC left SPL are involved in
attentional bias in smokers. Groupmedication interac-
tions and the lack of group differences after haloperidol
suggest that brain activation associated with attentional bias
in smokers is normalized when dopamine levels are reduced
by haloperidol. Paired t-tests, however, did not reveal
significant medication effects in either smokers or non-
smokers at the FWE-corrected level. We therefore extracted
parameter estimates in those regions showing a whole brain
Figure 2 Behavioral measures for the attentional bias line-counting task. Repeated-measures analyses of variance for accuracy rates and reaction times
during line counting showed that both smokers and non-smoking controls were less accurate for smoking-related pictures and showed shorter reaction
times for smoking-related pictures. Both groups were less accurate after haloperidol.
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groupmedication interaction and significant group dif-
ferences (dACC and r-DLPFC). Subsequently, paired sample
t-tests in SPSS were performed for both groups separately.
Results showed a significant reduction in brain activation in
smokers for the r-DLPFC, t(24)¼ 3.07, po0.01, and a trend
for the dACC, t(24)¼ 1.99, po0.058. Brain activation in the
r-DLPFC was significantly increased by haloperidol for non-
smokers, t(23)¼ 2.67, po0.05.
Brain activation associated with attentional bias in smokers
was neither positively nor negatively correlated with cue-
evoked craving during task performance in any of our a
priori defined regions of interest. See Supplementary Tables 7
and 8 for (nonsignificant) correlation coefficients between
craving and brain and behavioral indices of attentional bias.
DISCUSSION
The main purpose of this study was to investigate whether
brain activation associated with attentional bias in smokers
could be modulated by a dopamine antagonist. The current
results provide support for the proposed role of dopamine
in attentional bias. In line with our hypotheses, smokers
showed increased activation associated with attentional bias
in the dACC, right DLPFC, and left SPL after placebo,
whereas this activation was normalized when dopamine
levels were reduced following administration of a dopamine
antagonist. That is, no differences in brain activation
between smokers and non-smokers were found after
haloperidol intake. These results are in line with a previous
study showing that the dopamine antagonist amisulpride
normalized cue-induced brain activation in alcohol-depen-
dent patients (Hermann et al, 2006).
The current findings replicate and extend findings of our
previous study using the same pictorial attentional bias task
(Luijten et al, 2011). Again, our results implicate a role for
the dACC in attentional bias in smokers. The dACC is
known to be involved in multiple cognitive processes
(Shackman et al, 2011) such as salience detection (Seeley
et al, 2007), behavioral monitoring, and top–down control
of attention (Bush et al, 2000; Weissman et al, 2005). The
dopaminergic signal in the striatum evoked by conditioned
substance cues (Volkow et al, 2006; Wong et al, 2006;
Zijlstra et al, 2008) may modulate dACC activation via
connections between the dACC and the ventral striatum
(Kunishio and Haber, 1994) such that the salience of these
cues is detected. Meanwhile, the dACC may signal conflict
of attentional resources, because attention is automatically
allocated to the substance cues and withdrawn from
ongoing behavior. Given the multi-functionality of the
dACC (Shackman et al, 2011), we suggest that the dACC is
involved in salience detection of conditioned substance cues
and subsequent allocation of additional cognitive resources.
To increase cognitive control for the continuation of
ongoing behavior during smoking-cue exposure, the ACC
may cooperate with the DLPFC, a region that was also found
to be associated with attentional bias in smokers. For
example, it has been shown that coactivation of the dACC
and DLPFC contributes to the implementation of adjust-
ments in activation of future behavior (Kerns et al, 2004). In
this study, we showed that when dopamine transmission in
response to conditioned smoking cues is reduced by a
dopamine antagonist, the activation in the dACC and
Figure 3 Group differences for brain activation associated with attentional bias. *po0.05 FWE small volume corrected both with and without masking for
the groupmedication interaction, +po0.05 FWE small volume corrected only without masking for the groupmedication interaction. The values on the
Y axis represent contrast values for LCSP minus LCNP, consequently positive values on the Y axis indicate more brain activation for line counting when
smoking-related pictures are presented on the background relative to when neutral pictures are presented on the background. FWE, family wise error;
LCNP, line-counting neutral picture; LCSP, line-counting smoke picture; l, left; r, right; dACC, dorsal anterior cingulate gyrus; DLPFC, dorsolateral prefrontal
cortex; SPL, superior parietal lobe.
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DLPFC associated with attentional bias in smokers is
reduced accordingly. For future studies, it would be
interesting to examine whether individual differences in
dopaminergic activation in smokers are associated with
differences in attentional bias-related brain activation.
Although the dopaminergic theory for attentional bias does
not involve an inverted U-shape aspect as yet, it may be that
the association between dopamine and the attentional
control aspects of attentional bias, follows a similar inverted
U-shape curve as previously described in the domain of
cognitive control (Cools and D’Esposito, 2011). In studies
addressing this hypothesis, a group of smokers with a broad
range of attentional bias scores should be included to
sample all parts of the U-shaped curve. Also, dopamine
levels would preferably be measured with PET in order to
obtain a more direct estimation of dopamine levels.
The findings in this study provide a proof of principles
for the role of dopamine in attentional bias-related brain
activation and may guide the development of new
pharmacotherapies for smoking addiction. However, some
findings in this study suggest that the association between
dopamine and controlling substance-related behavioral may
be rather complex. First, it was found that haloperidol
reduced overall performance accuracy and activation in the
medial prefrontal and bilateral DLPFC during line counting
(see Supplementary Table 5) suggesting that dopamine
antagonists may reduce overall cognitive control. Given that
reduced cognitive control is also associated with problems
controlling substance use (Feil et al, 2010; Goldstein
and Volkow, 2011), a reduction in cognitive control may
constitute an unfavorable effect. Second, the single dose of
haloperidol was not able to reduce subjective craving in
smokers, which is in line with previous studies failing to
show reduced craving after a short term reduction in
dopamine levels (Ersche et al, 2010; Franken et al, 2004;
Hitsman et al, 2008; Munafo et al, 2007). Various
explanations exist for the discrepancy in findings between
attentional bias-related brain activation and subjective
craving. First, we could not replicate the association
between attentional bias-related brain activation and
subjective craving as shown in our previous study (Luijten
et al, 2011). This inconsistency remains currently unre-
solved, as previous imaging studies investigating attentional
bias in addicted individuals have not examined this
association (Ersche et al, 2010; Hester and Garavan, 2009;
Janes et al, 2010a, b; Nestor et al, 2011). The discrepancy in
effects of the dopaminergic manipulation as well as the lack
of a consistent association between attentional bias-related
brain activation and craving may arise as a consequence of
differences between phasic and tonic dopamine neuro-
transmission. Phasic dopamine transmission has been
suggested to be involved in attentional bias, whereas tonic
dopamine levels may mediate symptoms associated with
withdrawal such as subjective craving (Hitsman et al, 2008).
Furthermore, it has been proposed that brain activation is a
rather sensitive measure to detect abnormalities in addicted
individuals regarding cue reactivity compared to other
subjective measures such as craving (Goldstein and Volkow,
2011). The latter is also in line with behavioral data in this
study that could not differentiate between smokers and
non-smokers. In fact, behavioral data indicated that
smoking-related pictures disrupt ongoing behavior in both
groups indicating that brain activation differences between
groups after placebo should be interpreted as increased
neural effort in smokers to reach similar performance.
Enhanced activation in non-smokers for picture naming of
smoking-related vs neutral pictures (see Supplementary
Table 4) further support that non-smokers may react stronger
to smoking cues. Although interference for smoking cues in
non-smokers is not typically found, a previous study that
also showed this interference effect in non-smokers sug-
gested that it may be due to non-addiction reasons such as
negative valence (Stippekohl et al, 2012). Another unexpected
finding in non-smokers is that brain activation associated
with attentional bias after haloperidol was significantly
increased. Activation patterns (see Figure 3) suggest that
non-smokers are characterized by reduced activation for
line counting in smoking-related pictures relative to neutral
pictures after placebo, an effect that disappeared after
haloperidol administration. Although highly speculative, we
suggest that the increase in brain activation in the DLPFC
for smoking-related pictures reflects an attempt to prevent
a further decrement in performance levels as performance
is lowest after haloperidol and for smoking-related pictures
in general.
A final important consideration regarding this study is that
smokers did not smoke for 4 h before testing as this could
have interfered with medication effects. Given this study
design, we cannot completely rule out withdrawal effects on
our results. We could demonstrate, however, that withdrawal
was not influenced by medication type and was not
associated with individual differences in task performance
Table 1 Group Differences for Brain Activation Associated with
Attentional Bias




Left dACC 2 2 36 4.00 360b
Right DLPFC 24 44 46 4.03 456








Abbreviations: dACC: dorsal anterior cingulate cortex; DLPFC, dorsolateral
prefrontal gyrus; SPL, superior parietal lobe.
apo0.05 FWE small volume corrected.
bAfter masking with the groupmedication interaction the size of this cluster
reduced to 176mm3.
cAfter masking with the groupmedication interaction this cluster no longer
met the requirements to correct for multiple comparisons.
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(see Supplementary materials). In our previous study
showing similar attentional bias-related brain activation
(Luijten et al, 2011), smokers were abstinent for 3 h, whereas
smokers smoked did not abstain in other studies investigat-
ing attentional bias-related brain activation in smokers
(Janes et al, 2010a, b; Nestor et al, 2011; Stippekohl et al,
2012). Generally, it is assumed that attentional bias is
augmented after longer periods of abstinence (Waters and
Feyerabend, 2000), therefore the 4 h abstinence period is
important to consider when interpreting the current results.
To conclude, it was shown that administration of a
dopamine antagonist normalized activation associated with
attentional bias in the dACC and DLPFC in smokers. This
finding supports theoretical accounts of the role of
dopamine in attentional bias, and may have implications
for the development of new pharmacotherapies for smoking
addiction. However, our finding that haloperidol reduced
overall task performance and associated brain activation
indicates that it should be a future research agenda to
investigate whether an optimal balance of dopamine in
different brain regions in smokers can be achieved.
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